(thirdQuint)Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer.

 This is a phase 2, single arm study.

 Participants will be treated with combination Gemzar, Abraxane and Avastin therapy until disease progression.

 Each treatment cycle is 28 days.

.

 Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer@highlight

The investigators hypothesize that the combination of Gemzar(R), Abraxane(R) and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with definable metastatic disease, 6 or more months after primary treatment.

